Hepatitis C News and Research

Latest Hepatitis C News and Research

Phase 1 clinical trial starts for new antibody aimed at hepatitis C virus

Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).

6 Aug 2009

Ichor Medical Systems awarded $3.3 million to develop Alzheimer’s vaccine

Ichor Medical Systems of San Diego has announced that it has been selected to receive a $3.3 million grant award from the National Institute of Neurological Disorders and Stroke (NINDS) for development of a vaccine for Alzheimer’s disease.

6 Aug 2009

Structure of an entire HIV genome decoded

The structure of an entire HIV genome has been decoded for the first time by researchers at the University of North Carolina at Chapel Hill. The results have widespread implications for understanding the strategies that viruses, like the one that causes AIDS, use to infect humans.

5 Aug 2009

Mortality rates higher in hepatitis C virus carriers

Hepatitis C virus (HCV) is a blood-borne disease that causes inflammation of the liver and to which there is currently no vaccine available. The World Health Organization (WHO) estimates that 3% of the world's population, approximately 170 million people, are infected with HCV and it is a leading cause of liver cirrhosis, end stage liver disease, hepatocellular carcinoma (HCC) and liver transplantation.

31 Jul 2009

Hepatitis C infection: Treatment options equally effective, likelihood of success known early on

Results of a long-awaited study of 3,070 American adults at Johns Hopkins and 118 other U.S. medical centers show that treatment with either of the two standard antiviral drug therapies is safe and offers the best way for people infected with hepatitis C to prevent liver scarring, organ failure and death.

22 Jul 2009

Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV

Schering-Plough Corporation has announced that it has extended to stage two an ongoing Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. In this study, vicriviroc is being evaluated in a novel nucleoside-sparing regimen that is designed to provide additional options for treatment-naive patients in a once daily regimen, while preserving other drug classes for subsequent lines of treatment.

15 Jul 2009

Focusing HIV treatment helps control concurrent hepatitis B infection

Prolonged use of highly active antiretroviral therapy (HAART) to treat people infected with both HIV and hepatitis B (HBV) helps to better control the hepatitis B infection and could delay or prevent liver complications, according to a new study by researchers at Wake Forest University School of Medicine.

15 Jul 2009

Kenya seeks support from PEPFAR to expand blood transfusion centers

Kenya's Medical Services Permanent Secretary James Ole Kiyiapi announced Thursday that the government is in negotiations with PEPFAR for support in building additional blood transfusion centers in the country, Capital News reports.

29 Jun 2009

New media-led effort responds to AIDS crisis in black America

Today, leading U.S. media companies announced a new coordinated national campaign to mobilize Black Americans in response to AIDS and promote specific calls-to-action to prevent and reduce the further spread of HIV. Greater Than AIDS - a multi-faceted campaign presented under a common brand that includes targeted public service ads (PSAs) as well as integrated messages in news, entertainment and community content - seeks to strengthen a sense of community among Black Americans in response to HIV/AIDS.

25 Jun 2009

Transplant drug Rapamycin stimulates immune memory

Rapamycin, a drug given to transplant recipients to suppress their immune systems, has a paradoxical effect on cells responsible for immune memory, scientists at the Emory Vaccine Center have discovered.

22 Jun 2009

Trial of new ‘combo’ treatment for hepatitis C

In a multi-center trial led by a Saint Louis University researcher, investigators found that a new combination therapy of daily consensus interferon and ribavirin helps some hepatitis C patients who have not responded to previous treatment.

17 Jun 2009

Research supports world blood donor day message on blood safety

Other countries could learn from the mistakes made in UK blood policy concludes research awarded by the Economic and Social Research Council's Michael Young Prize.

13 Jun 2009

Study shows promise for new cancer-stopping therapy

Researchers at Nationwide Children's Hospital and Johns Hopkins University have discovered that delivering a small molecule that is highly expressed in normal tissues but lost in diseased cells can result in tumor suppression.

12 Jun 2009

HCV protease inhibitor telaprevir improves response, halves treatment time for hepatitis C patients

For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.

5 Jun 2009

Johnson & Johnson's research reflecting new Washington policies

Health care supplier Johnson & Johnson will focus on new treatments and improved tests for cancer and other diseases for which company perceives unmet needs, like diabetes, hepatitis C, and HIV, as well as using new, Washington-supported research techniques to gauge their effectiveness, researchers and executives said at a briefing with analysts, BusinessWeek reports.

5 Jun 2009

Blood pressure drug reverses liver damage

British scientists have discovered that blood-pressure drugs can reverse the effects of early-stage liver failure in some patients.

1 Jun 2009

MicroRNAs grease the cell's circadian clockwork

Most of our cells possess an internal clock, a group of genes displaying a cyclic expression pattern that reaches a peak once a day. A large number of circadian genes are expressed by organs such as the liver, whose activity needs to be precisely regulated over the course of the day.

31 May 2009

Blood-pressure medicine shown to reverse the effects of early-stage liver failure

Newcastle University researchers analysed a small clinical trial of losartan, a drug normally prescribed for hypertension, on 14 patients in Spain, who had Hepatitis C.

31 May 2009

Thai HIV/AIDS advocates urge increased treatment access for IDUs

The Thai AIDS Treatment Action Group recently called on the country to launch a comprehensive harm reduction program for injection drug users in an effort to help curb the spread of HIV, Thailand's The Nation reports.

31 May 2009

'Complacency,' 'stigma' hindering efforts to reduce HIV/AIDS in black communities, opinion piece says

"Nearly 30 years after the discovery of HIV and AIDS, the epidemic is still ravaging black neighborhoods in Baltimore and across the nation," Kevin Fenton -- director of CDC's National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention -- writes in a Baltimore Sun opinion piece.

28 May 2009